LUGPA 2021 Annual Meeting

November 11-13, 2021 - Chicago, IL

Visit us at LUGPA 2021 to learn more about how the Oncotype test portfolio helps guide treatment decisions for your localized to advanced prostate cancer patients.

Oncotype MAP Pan-Cancer Tissue Test Webinar

What Can We Learn from NSCLC?

Learn how NGS-based comprehensive genomic profiling has enhanced patient care through real-world NSCLC case studies, presented by Drs. Edgardo Santos, Snehal Thakkar, and Jean-Paul De La O.

UroCareLive Webinar

Available Now On-Demand

Drs. Sellinger and Shore discuss “Incorporating Genomic Profiling and Biomarker Testing in Clinical Practice” using the Oncotype tests for advanced prostate cancer patients.

New Cut Point for Unfavorable Intermediate and High-Risk Patients

Oncotype DX Genomic Prostate Score

The Oncotype DX GPS assay stratifies unfavorable intermediate and high-risk patients into two distinct groups with highly differing long-term outcomes.

Medicare Coverage Update

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score Assay is now covered by Medicare for all intermediate-risk prostate cancer patients.
Making cancer care smarter.™